PWA
BMY icon

Provenance Wealth Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Provenance Wealth Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-360
Closed -$16.2K – 421
2025
Q3 		$16.2K Sell
360
-65
-15% -$3.04K ﹤0.01% 308
2025
Q2 		$19.7K Sell
425
-175
-29% -$8.59K ﹤0.01% 269
2025
Q1 		$36.6K Sell
600
-32
-5% -$1.86K 0.01% 239
2024
Q4 		$35.7K Sell
632
-395
-38% -$22.1K ﹤0.01% 238
2024
Q3 		$53.1K Buy
1,027
+430
+72% +$20.2K 0.01% 230
2024
Q2 		$24.8K Sell
597
-65
-10% -$2.91K ﹤0.01% 245
2024
Q1 		$35.9K Buy
662
+65
+11% +$3.31K 0.01% 239
2023
Q4 		$30.6K Sell
597
-15,342
-96% -$805K ﹤0.01% 234
2023
Q3 		$925K Buy
+15,939
New +$977K 0.15% 57

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Provenance Wealth Advisors's BMY Position: Q4 2025 in Review

Provenance Wealth Advisors sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 360 shares — an estimated $16.2K sold.

Provenance Wealth Advisors first reported a position in BMY in Q3 2023 and held it in 9 quarters. The position peaked at $925K in Q3 2023. 2,454 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Provenance Wealth Advisors reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Provenance Wealth Advisors sold 360 Bristol-Myers Squibb shares in Q4 2025, an estimated $16.2K.
  • Provenance Wealth Advisors first reported a position in Bristol-Myers Squibb in Q3 2023 and held it in 9 quarters.
  • Provenance Wealth Advisors's Bristol-Myers Squibb position peaked at $925K in Q3 2023.
  • 2,454 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Provenance Wealth Advisors's 13F filing for Q4 2025, filed 26 Jan 2026.